|
A firm's use of social media faces FDA restrictions and obligations on how you use social media, what you can say and what you must do to correct misinformation published by third parties that places you at risk with FDA. Social media gives firms a broad demographic reach to potential customers. Some of that activity is acceptable to FDA, some are not, and will earn you an FDA Warning Letter. That is a costly regulatory rebuke, which you can avoid. Planning and ongoing diligence is required Planning and ongoing diligence is required. Mr. Uldrik in this webinar will provide insight on how to manage marketing strategies that use social media. Join this webinar to
learn more.
Key Learning Objectives
- How FDA limits the use of social media
- How social media can make your product illegal (misbranded)
- Who triggers the off-label trap
- Figure out who is responsible for false or misleading information
- Identify corporate controls over regulatory affairs and marketing departments
|
|
|
|
|
|
|
|
Casper E Uldriks
Mr. Uldriks held a number of positions at FDA, such as an investigator in FDA's New England office, in the Office of the Commissioner in Legislative Affairs and in the Center for Devices and Radiological Health (CDRH), where he served as CDRH's Associate Director for Regulatory Guidance and Government Affairs. He helped to guide CDRH to develop and implement various medical device related amendments to the Food, Drug, and Cosmetic Act, regulations and guidance documents.
|
|
View More
|
|
|
|
|
Host This Webinar At Your Organization
Become a Speaker
